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Tissue homeostasis over the life of an organism relies on both self-renewal and multipotent differentiation of
stem cells. Hematopoietic stem cells (HSCs) reside in a hypoxic bone marrow environment, and their meta-
bolic status is distinct from that of their differentiated progeny. HSCs generate energy mainly via anaerobic
metabolism by maintaining a high rate of glycolysis. This metabolic balance promotes HSC maintenance by
limiting the production of reactive oxygen species, but leaves HSCs susceptible to changes in redox status.
In this review, we discuss the importance of oxygen homeostasis and energy metabolism for maintenance of
HSC function and long-term self-renewal.The unique and defining characteristic of stem cells is the
capacity for self-renewal and multipotent differentiation, which
enables them to maintain tissue homeostasis throughout an
organism’s life span. Genetic analyses using mutant model
animals have identified essential regulators in numerous stem
cell systems. Transcriptome, epigenome, and proteome studies
have also provided important insights into stem cell biology
(Macarthur et al., 2009). These studies have led to the proposal
that specific metabolic properties are required to maintain self-
renewal and the multipotent differentiation capacities of stem
cells. Because stem cells are maintained in the body for long
periods, they must defend themselves against a variety of phys-
iological stresses. How stem cells avoid, endure, or are de-
stroyed by stresses is an essential question in stem cell biology
and aging.
The hematopoietic system consists of stem cells, transient
amplifying (progenitor) cells, and mature (differentiated) cells.
This remarkable system generates 2 3 1011 erythrocytes per
day, or over 5,000,000,000,000,000 red cells during the course
of an average human lifetime. This long-term cell production
depends on the presence of hematopoietic stem cells (HSCs),
which can give rise to additional stem cells (i.e., exhibit self-
renewal) and to progenitor cells (i.e., exhibit differentiation).
Technical advances have meant that HSCs are the best-
characterized stem cell, thanks to our ability to undertake pro-
spective isolation, conduct real-time cellular tracking, and eval-
uate stem cell capacity (Orkin and Zon, 2008).
In this article, we discuss recent insights into HSCmetabolism
and the mechanisms that regulate HSC bioenergetics. We also
outline how energy, oxygen, and redox homeostasis are interre-
lated and how their balance is essential for HSC maintenance.
Quiescent and Cycling HSCs
HSC research has advanced significantly through a combination
of stem cell purification and functional assays. Through HSC
isolation based on surface markers, it has become clear that
cell cycle status is critical for HSC function. Stem cells are
conventionally classified as being in either quiescent or cycling298 Cell Stem Cell 9, October 7, 2011 ª2011 Elsevier Inc.states, and quiescence is generally viewed as a mechanism for
avoiding accumulation of damage resulting from physiological
stress (Figure 1). HSCs and progenitor cells are included in the
heterogeneous population of Lineage-marker, Sca-1+, and
c-Kit+ (LSK) cells. Among these cells, CD34, CD150hi, and
side population (SP) cells (Osawa et al., 1996; Kiel et al., 2005;
Goodell et al., 1996) are slow cell cycling.
Classical cell cycle analyses of highly purified HSCs that
measure DNA content (by amount of staining with Hoechst
33342 or 40,6-diamidino-2-phenylindole) either alone or com-
bined with intracellular Ki67 expression (which is absent in the
quiescent G0 stage) indicate that more than 70% of
CD34CD48CD150hiLSK HSCs are in G0, whereas less than
10% of more differentiated multipotent progenitor (MPP) cells
(CD34+ LSK cells) are quiescent (Wilson et al., 2008). Different
mathematical modeling strategies using label decay kinetics
data indicate that the CD34CD48CD150hiLSK HSC popula-
tion probably consists of both a dormant population (30%),
which divides only every 145–193 days, and a ‘‘homeostatic’’
population (70%; previously called ‘‘activated HSCs’’), which
divides every 28–36 days (Wilson et al., 2008). Similarly, Taki-
zawa et al. (2011) showed that fast-cycling (undergoing four to
seven divisions in 7 weeks) and quiescent (undergoing no divi-
sions in 12–14 weeks) cells are present in steady state murine
bone marrow (BM) by labeling the stem cells with carboxyfluor-
escein succimidyl ester (CFSE).
Generally, slow cycling HSCs possess long-term (LT) reconsti-
tution activity when they are transplanted into lethally irradiated
mice, whereas actively cycling stem cells and progenitors exhibit
only short-term (ST) reconstitution, and cannotmaintain hemato-
poiesis for more than 3–4 months. Thus, the former are termed
LT-HSCs and the latter are ST-HSCs. LT-HSCs produce
ST-HSCs that in turn give rise to MPPs, lineage-restricted
progenitors, and terminally differentiated hematopoietic cells
(Figure 1). MPPs that accumulate genomic or epigenomic errors
can be eliminated by cell cycle checkpoints and apoptosis.
LT-HSCs protect themselves from DNA damage by limiting their
cell cycle frequency, but some damage does still accumulate
Figure 1. Differentiation of Hematopoietic
Stem Cells
Long-term hematopoietic stem cells (LT-HSCs)
are at the top of the hematopoietic hierarchy and
are classified into two states, quiescent and
cycling. LT-HSCs produce short-term (ST)-HSCs
followed by multipotent progenitors (MPPs),
lineage-restricted progenitors, and terminally dif-
ferentiated hematopoietic cells.
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stem cells are more resistant to cytotoxic agents, such as ultra-
violet (UV) light, ionizing radiation, and chemicals, when com-
pared with actively cycling cells, because these agents affect
cells that are in the S or M phase of the cell cycle (Figure 2).
Distinctive DNA damage responses (DDRs) and DNA repair
mechanisms, which render stem cells stress tolerant, have
been uncovered recently (Blanpain et al., 2011). DNA double
strand breaks (DSBs) that do occur during G0 in HSCs are imme-
diately repaired by nonhomologous end joining, which tends to
be more error prone than homologous recombination (Branzei
and Foiani, 2008). Such error-prone repair may contribute to
stem cell senescence, apoptosis, and leukemic transformation
(Rossi et al., 2007, 2008). Another feature of HSCs and some
other types of stem cell is high drug efflux capacity through
ATP-dependent transporters such as the breast cancer resis-
tance protein 1 (Bcrp1; also known as Abcg2), thereby prevent-
ing accumulation of toxic compounds (Challen and Little, 2006).
Experimental data indicates that quiescent stem cell popula-
tions are present in several tissues. For example, in the hair
follicle, proliferation of stem cells in bulge regions is suppressed
by Wnt inhibitors (Fuchs and Horsley, 2011). However, stemFigure 2. Stem Cell Defense Mechanisms and Potential Stress
Responses
Bulleted points indicate stem cell properties that confer stem cell resistance to
various cytotoxic insults. After the cellular stress exposure, the fate of a cell is
survival, senescence, cell death, premature differentiation, or oncogenic
transformation.
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epithelia, which are marked by expres-
sion of a leucine-rich G protein-coupledreceptor (Lgr5) that functions as an R-spondin receptor (de
Lau et al., 2011), divide every 24 hr (Snippert and Clevers,
2011). It will be interesting to compare the mechanisms involved
in protection from environmental stress and DNA damage
between quiescent stem cells, such as HSCs and hair follicle
stem cells, and actively cycling populations, such as intestinal
stem cells.
Adaptation of HSCs to a Hypoxic Microenvironment
Several studies have suggested that LT-HSCs reside primarily in
the endosteal zone of the BM (Calvi et al., 2003; Zhang et al.,
2003; Arai et al., 2004). This region has unique vascular organiza-
tion (Draenert and Draenert, 1980). Nutrient arteries penetrate
the cortical bone, enter the medullary canal, and then proceed
in a spiral pattern into the metaphyseal region. The arterioles,
which arise from the smaller arteries, further subdivide into arte-
rial capillaries. The blood in these capillaries drains into sinu-
soids, which are loosely organized and fenestrated, enabling
hematopoietic cells to easily move across them. As a result,
perfusion of BM is limited and the partial pressure of oxygen
(PO2) in the endosteal region is very low.
In addition to having poor O2 delivery, the BM is densely popu-
lated with blood cells. O2 consumption by hematopoietic cells is
relatively high, and a simulation study of O2 diffusion in the BM
suggested that PO2 is decreased 10-fold at a distance of several
cells from the nearest capillary (Chow et al., 2001). The average
PO2 in BM is approximately 55mmHg, andmeanO2 saturation is
87.5% (Harrison et al., 2002). Thus, based on this simulation,
HSCs may well reside in a severely hypoxic environment.
Experimental data also support the idea that murine HSCs are
located in a hypoxic BM niche. Parmar et al. (2007) administered
a perfusion tracer into mice and found that HSCs were relatively
enriched in a low-perfusion cellular compartment in the BM. In
parallel, retention of pimonidazole, a probe that selectively forms
adducts with protein thiol groups under hypoxic conditions, was
observed in hypoperfused cells. Administration of tirapazamine,
a toxin selective for hypoxic cells, promoted loss of HSCs in vivo.
Also, Simsek et al. (2010) and Takubo et al. (2010) showed that
LT-HSCs are pimonidazole+ in vivo. Moreover, human cord
blood HSCs transplanted into superimmunodeficient NOD/
scid/IL-2Rg (NOG) mice reacquired both hypoxic status and
cell cycle quiescence after transplantation (Shima et al., 2010).
Thus, these findings lead overall to a model in which the
hypoxic character of LT-HSCs is determined by their position
within the BM. However, in contrast to the simple O2 gradient
model for the BM hypoxic niche, 2D observation of a segment, October 7, 2011 ª2011 Elsevier Inc. 299
Figure 3. HIF-1a Function in HSCs
(A) Shown is a representation of HIF-1a protein
and interacting regulatory factors. HIF-1a is a
substrate for both prolyl and asparaginyl hydrox-
ylases. Under normoxia, proline and asparagine
residues are hydroxylated by specific dioxyge-
nases, modifications that regulate their stability
and transcriptional activity. bHLH, basic-helix-
loop-helix domain; PAS, Per-ARNT-Sim domain;
TAD-N, transactivation domain N-terminal; ID, in-
hibitory domain; TAD-C, C-terminal transactiva-
tion domain; PHD, prolyl hydroxylase domain-
containing protein; and FIH-1, factor-inhibiting
HIF-1.
(B) Schematic representation of outcomes
following HIF-1a or VHL deletion in HSCs.
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vasculature (Kiel et al., 2005; Sugiyama et al., 2006). At face
value, this finding does not seem consistent with HSCs being
hypoxic. However, as noted above, the capillaries in the endos-
teal zonemay perfuse the BM very poorly. In addition, time-lapse
3D tracking of single LT-HSCs has provided information thatmay
solve this apparent paradox. Real-time imaging of murine BM in
calvaria revealed that HSCs gradually move away from vessels
and then dive deep into the osteoblastic region of the BM after
transplantation (Lo Celso et al., 2009; Xie et al., 2009). Thus, it
is possible that subpopulations of HSCs residing in different
specific locations exist in different cell cycle and/or metabolic
states.
Consistent with the idea of a hypoxic niche in vivo, analysis of
HSCs in culture also indicates that their function is maintained
most effectively under hypoxic conditions. It is well established
that colony-forming ability or transplantation capacity increases300 Cell Stem Cell 9, October 7, 2011 ª2011 Elsevier Inc.when BM cells are cultured under hyp-
oxic conditions (Cipolleschi et al., 1993;
Danet et al., 2003; Ivanovic et al., 2004).
Hypoxia also induces quiescence in
cultured hematopoietic cells (Hermitte
et al., 2006; Shima et al., 2010). In flow
cytometric analysis, quiescent LT-HSCs
constitute the SP fraction, which is
defined by their high efflux of the DNA-
labeling dye Hoechst 33342 (Goodell
et al., 1996). Hypoxia also maintains the
SP phenotype in HSC cultures (Krishna-
murthy et al., 2004). Exclusion of Hoechst
dye from HSCs is mediated by Bcrp1, an
ATP-dependent transporter. When HSCs
were cultured under hypoxic condi-
tions, Bcrp1 expression increased, as
did the number of SP cells, as compared
with HSCs cultured under nonhypoxic
conditions.
The Hypoxia Response Machinery
in HSCs
The hypoxia-responsive regulatory path-
ways that exist in HSCs are similar to
those seen in a number of other cell
types. A key component is hypoxia-inducible factor-1 (HIF-1), a transcription factor that is essential
for cellular and systemic responses to reduced O2 availability
(Semenza, 2010) (Figure 3A). HIF-1 is a heterodimeric protein
consisting of the O2-regulated HIF-1a subunit and a constitu-
tively expressed HIF-1b subunit (Wang and Semenza, 1995).
Under normoxic conditions, HIF-1a is hydroxylated at proline
(Pro) 402 and/or 564 in the O2-dependent degradation (ODD)
domain (Kaelin and Ratcliffe, 2008) by three prolyl hydroxy-
lases, PHD1–3, which require O2, Fe
2+, 2-oxoglutarate (2-OG;
a-ketoglutarate), and ascorbate for enzymatic activity (Epstein
et al., 2001). Prolyl-hydroxylated HIF-1a is recognized by the
von Hippel-Lindau (VHL) tumor suppressor protein, which
recruits the Elongin C/Elongin B/Cullin2/E3-ubiquitin-ligase
complex, leading to ubiquitination and subsequent proteasomal
degradation. Under hypoxic conditions, HIF-1a prolyl hydroxyl-
ation is suppressed, stabilizing HIF-1a protein (Kaelin and Rat-
cliffe, 2008). HIF-1a:HIF-1b heterodimers bind to hypoxia
Figure 4. Stabilization of HIF-1a Protein after Hypoxic Exposure
Immunocytochemical detection of HIF-1a (green), FoxO3a (red), and c-Kit
(gray) in HSCs (CD34 LSK cells) exposed to 12 hr of hypoxia (right) or nor-
moxia (left) without cytokines. Preferential stabilization of HIF-1a was
observed in HSCs under hypoxia (modified from Takubo et al., 2010).
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vate transcription (Semenza, 2010).
HIF-1 mRNA and protein are highly expressed in LT-HSCs
(Takubo et al., 2010; Simsek et al., 2010) (Figure 3B and Figure 4).
Analysis of HSCs derived from conditional HIF-1a knockout
(HIF-1aD/D) mice showed that they lost the capacity for marrow
reconstitution during serial BM transplantation (Takubo et al.,
2010). HIF-1aD/D LT-HSCs entered the cell cycle from G0, prolif-
erated, and showed reduced tolerance to stresses such as
5-fluorouracil administration or aging. These studies provided
evidence that HIF-1a plays an essential role in the maintenance
of HSC quiescence and stress resistance. To complement these
HIF-1a loss-of-function studies, conditionally deleted the VHL
gene in hematopoietic cells, which results in HIF-1a gain of func-
tion. Analysis of these cells revealed that the properties of LT-
HSCs and progenitors are differentially influenced by HIF-1a,
and that HIF-1a protein levels are elevated in either biallelic
(VHLD/D) or monoallelic (VHL+/D) conditional knockout mice.
Interestingly, although a small fraction of normal hematopoietic
progenitors (CD34+ LSK cells) are in G0 phase, the proportion
of VHL+/D hematopoietic progenitors in G0 is significantly higher.
HIF-1a protein levels are not high in hematopoietic progenitors at
steady state, and stabilization of HIF-1a protein throughmonoal-
lelic VHL deletion both induces exit of VHL+/D hematopoietic
progenitors from the cell cycle andmaintains them in a quiescent
state. Aberrant suppression of cell cycling and transplantation
capacity is restored in HIF-1aD/D:VHLD/D double-knockout
HSCs. The decreased frequency of LT-HSCs seen in VHLD/D
mice is rescued by codeletion of the HIF-1a gene. In addition,
long-term in vitro treatment of LT-HSCs with a PHD inhibitor,
dimethyloxalylglycine, which also stabilizes HIF1-a, especially
attenuates stem cell capacity during BM transplantation (Elias-
son et al., 2010).
Taken together, these results indicate that there is an optimal
HIF-1a protein level for HSC maintenance. HIF-1a is required for
long-term HSC maintenance, and within a given range,
moderate increases of HIF-1a are beneficial for HSCs through
the induction of quiescence. However, excess HIF-1a is detri-
mental to HSCs and leads to destabilization and premature
exhaustion. Thus, HIF-1a finely regulates stem cell proliferation
and differentiation, and it will be important to understand how
the level of HIF-1a transcript and protein regulates HSC activity.
In this regard, a new study of this issue shows that one of the heatshock proteins, GRP78, and its ligand, Cripto, regulate HSC
quiescence and maintain HSCs in hypoxia as an intermediary
of HIF-1a (Miharada et al., 2011). The Cripto promotor region
has an HRE, onto which the stabilized HIF-1 complex binds.
Heat shock proteins are also involved in protecting HIF-1a
in the AKT signaling pathway, which is covered later in this
article.
HIF-1a also plays an important role in neural stem cells (NSCs)
under hypoxic conditions. In these cells, HIF-1a reportedlymedi-
ates activation of Wnt/b-catenin signaling through upregulation
of b-catenin and expression of the downstream transcription
factors lymphoid enhancer-binding factor 1 and T cell factor 1
(Mazumdar et al., 2010). Wnt/b-catenin activity was closely
correlated with hypoxic regions in the subgranular zone of the
hippocampus, which is a niche for NSCs. Loss of HIF-1a in
NSCs attenuated Wnt-dependent hippocampal neurogenic
niche capacity, as reflected by NSC proliferation, differentiation,
and production of new neurons. The biological effect of HIF-1a
on these stem cells (proliferation) appears to differ from that
seen in HSCs (quiescence). It will be of interest to dissect how
these different stem cell systems utilize the same HIF-1a protein
to maintain themselves using distinct molecular machinery and
biological events. Because embryonic HSCs actively proliferate
in hypoxic conditions, HIF-1a may promote HSC proliferation in
that context as well. HIF-1a has also been reported to inhibit
Wnt/b-catenin activity in cancer cells (Kaidi et al., 2007), sug-
gesting that the interaction of HIF-1a and Wnt/b-catenin in
stem/progenitor cells may differ from that seen in more differen-
tiated cell types.
HIF-1 Reprograms Glucose Metabolism in Hypoxic Cells
The downstream biochemical effects of HIF-1 activation have
been analyzed quite extensively, although not specifically in
HSCs. Simsek et al. (2010) showed that HSCs have low mito-
chondrial activity and increased glycolysis, but the majority of
our understanding of these pathways comes from studying other
cell types. Under hypoxic conditions, cells increase flux through
the glycolytic pathway via HIF-1-dependent transcriptional acti-
vation of genes encoding glucose transporters such as glucose
transporter 1 (GLUT1), glycolytic enzymes such as lactate dehy-
drogenase A (LDHA), andmetabolic regulatory enzymes such as
pyruvate dehydrogenase kinase 1 (PDK1) (Iyer et al., 1998).
HIF-1 mediates an active switch from oxidative to glycolytic
metabolism (see Semenza, 2009; Luo et al., 2011; Wheaton
and Chandel, 2011 and references therein). A key decision point
in glucose metabolism occurs at pyruvate, which can be con-
verted into lactate by LDHA or into acetyl-CoA by the mitochon-
drial enzyme pyruvate dehydrogenase (PDH) (Figure 5A). The
catalytic subunit of PDH is inactivated by phosphorylation via
PDK1, thereby shunting pyruvate away from mitochondria and
inhibiting O2 consumption.
Upstream of PDH, pyruvate kinase catalyzes the conversion of
phosphoenolpyruvate (PEP) plus ADP to pyruvate plus ATP.
Pyruvate kinase isoforms are encoded by the PKLR and PKM2
genes. PKLR encodes PKL, which is expressed in liver and
kidney, and PKR, which is expressed in red blood cells. PKM2
encodes PKM1 and PKM2, which are derived from alternatively
spliced mRNAs and contain sequences encoded by exon 9
and exon 10, respectively (Noguchi et al., 1986). PKM2 andCell Stem Cell 9, October 7, 2011 ª2011 Elsevier Inc. 301
Figure 5. Metabolic Pathways in Central Carbon Metabolism
(A) Extracellular glucose is taken up by cells and subjected to glycolysis (blue area), the pentose phosphate pathway (orange area), or the TCA cycle (green
area). G6P, glucose-6-phosohate; F6P, fructose-6-phosphate; F1,6BP, fructose-1,6-bisphosphate; DHAP, dihydroxyacetone phosphate; 1,3-BPG, 1,3-
bisphosphoglyceric acid; 2,3-BPG, 2,3-bisphosphoglyceric acid; 3-PG, 3-phosphoglycerate; PEP, phosphoenolpyruvate; 6PG, 6-phosphogluconate; Ru5P,
ribulose 5-phosphate; R5P, ribose 5-phosphate; S7P, sedoheptulose 7-phosphate; E4P, erythrose 4-phosphate.
(B) IDH mutations or TET deficiency results in abnormal hematopoiesis. Wild-type mitochondrial IDH2 catalytically converts Iso-citrate to 2-OG in the TCA cycle.
Mutated IDH2 (IDH2mut) and cytoplasmic IDH1 (IDH1mut) proteins acquire a new catalytic activity to convert 2-OG to 2-HG. 2-HG inhibits several histone de-
methylases and the TET1 and TET2 hydroxymethylases and stabilizes HIF-1a. In HSCs these alterations result in DNA hypermethylation, enhanced self-renewal,
and myeloproliferation. IDH1, isocitrate dehydrogenase 1; IDH2, isocitratedehyrogenase 2; 2-OG, 2-oxoglutarate; 2-HG, 2-hydroxyglutarate; HIF-1a, hypoxia-
inducible factor 1 alpha; TET1, Tet oncogene family member 1; TET2, Tet oncogene family member 2.
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(proliferative) and adult/differentiated (quiescent) cells, respec-
tively. PKM2 expression promotes cell proliferation and tumor
xenograft growth (Christofk et al., 2008). Although there is no
information yet about PKM activity in HSCs, it is likely that this
metabolic switch affects HSC function. PKM2 also promotes re-
programming of tumor metabolism from oxidative phosphoryla-
tion to glycolysis by acting as a HIF-1 coactivator. PKM2 binds to
the HIF-1a subunit and increases HIF-1 binding to HREs, recruit-
ment of the coactivator p300, histone acetylation, and transcrip-
tional activation of target genes such as PDK1 and LDHA (Luo
et al., 2011). The extent to which this pathway is activated in
HSCs or other stem cells has also not been determined.
It is assumed that hypoxic cells switch from oxidative to glyco-
lytic metabolism because O2 becomes limiting for respiration,
thereby necessitating utilization of a pathway that does not
require O2. However, the relationship between oxygen concen-
tration and metabolic switch is not straightforward. When wild-
type (WT) mouse embryo fibroblasts (MEFs) are switched from
20% to 1% O2, they reduce O2 consumption and continue to
consume less O2 even when they are switched back to 20%
O2, indicating that active and stable metabolic reprogramming
has occurred. HIF-1a/ MEFs do not switch from oxidative to
glycolytic metabolism when exposed to 1% O2, but they have
higher ATP levels at 1% O2 than WT MEFs do at 20% O2, indi-
cating that 1% O2 is not limiting for oxidative phosphorylation.
Why, then, do WT MEFs undergo a metabolic switch? The
answer appears to lie in reactive oxygen species (ROS) produc-
tion. HIF-1a/ MEFs maintained at %1% O2 for several days
die due to overwhelming ROS production, whereas WT MEFs302 Cell Stem Cell 9, October 7, 2011 ª2011 Elsevier Inc.exhibit lower ROS levels when maintained at 1% O2 for several
days than when maintained at 20% O2.
Survival of HIF-1a/ MEFs can be restored by overexpres-
sion of PDK1 or BCL2/adenovirus E1B 19 kDa interacting protein
3 (BNIP3), which triggers mitochondrial-selective autophagy.
Both proteins are encoded by HIF-1 target genes whose expres-
sion is induced by hypoxia in WT cells, suggesting that they are
functionally relevant mediators of this regulatory response. Both
also inhibit respiration, either by shunting substrates away from
mitochondria (PDK1) or by reducing mitochondrial number
(BNIP3). Increased ROS production in response to acute hyp-
oxiamay reflect inefficient electron transfer due to reduced avail-
ability of O2 as the terminal electron acceptor in complex IV
(cytochrome c oxidase, or COX). HIF-1 also directs a COX sub-
unit switch that may increase the efficiency of electron transfer
under hypoxic conditions, thereby reducing ROS production
(Fukuda et al., 2007).
Taken together, these findings indicate that HIF-1 orches-
trates molecular responses that maintain redox homeostasis in
the face of changing O2 levels. Thus, cells reduce their ROS pro-
duction under conditions of chronic hypoxia, but only if HIF-1 is
active. Future studies will hopefully be able to determine whether
these adaptive mechanisms are also active in HSCs and other
stem cells.
Mitochondrial Metabolism in HSCs
Cells require energy for proliferation, so it seems logical to
propose that stem cells would significantly alter their metabolism
as they transition from quiescence to an activated state. Quies-
cent HSCs depend more on glycolysis for ATP synthesis than on
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pathway generates a net of only 2 mol of ATP per mol of glucose
consumed, compared to oxidative phosphorylation, which gen-
erates 36 mol of ATP. In addition to ATP, a fundamental require-
ment for proliferation is a supply of precursor molecules for
biosynthesis of amino acids, lipids, and nucleotides. These
anabolic carbons are biosynthesized de novo mostly using inter-
mediates of the TCA cycle. Although glycolysis can rapidly
generate ATP to meet the energy requirements of biosynthesis,
active proliferation cannot be sustained given the limited flux
of glucose-derived intermediates to the TCA cycle. Therefore,
regulation of TCA cycle flux by limiting substrate/oxygen avail-
ability may represent another level of control for determining
HSC fate.
Peroxisome proliferator-activated receptor-g coactivator-1a
(PGC-1a) and PGC-1b have emerged as master regulators of
mitochondrial biogenesis. PGC-1a also regulates production of
various ROS detoxifying enzymes. PGC-1a is regulated by the
transcription factor c-Myc. Interestingly, c-Myc-deficient HSCs
can survive and proliferate normally but cannot differentiate,
suggesting that c-Myc is required in proliferating progenitors
rather than in quiescent stem cells (Laurenti et al., 2009).
c-Myc levels positively correlate with the cell cycle in HSCs
and are finely tuned by the E3 ubiquitin ligase Fbxw7, which is
upregulated under hypoxic conditions (Matsuoka et al., 2008;
Reavie et al., 2010; Iriuchishima et al., 2011). Consistent with
the idea that PGCs are master regulators of mitochondrial phys-
iology and metabolism (Gan et al., 2010), DePinho and his group
demonstrated in an elegant study that telomere dysfunction is
associated with impairedmitochondrial biogenesis and function,
decreased gluconeogenesis, and increased ROS production
(Sahin et al., 2011).
In studies of mitochondrial metabolism, there is increasing
interest in the role of autophagy, but analysis of this pathway in
HSCs is still only in its infancy. Autophagy is an evolutionarily
conserved cellular defense against starvation, and involves de-
gradation of cellular components via lysosomal activity in the au-
tophagosome (Mizushima and Levine, 2010). At least 18 different
Atg (autophagy-related) proteins function in this process. Auto-
phagy is negatively regulated by the mammalian target of rapa-
mycin (mTOR), which responds to growth factors and changes in
amino acid levels. Amino acids signal to mTOR through a Ras-
related small GTP-binding protein (Rag) (Sancak et al., 2008).
Thus, autophagy can be activated by amino acid depletion and
subsequent mTOR inhibition. Decreased ATP production stimu-
lates AMP-activated protein kinase (AMPK), which increases
autophagy not only indirectly through inactivation of mTOR,
but also directly through phosphorylation of a mammalian Atg1
homolog, Unc-51-like kinase 1 (Ulk-1) (Egan et al., 2011; Kim
et al., 2011). Ulk-1- or Atg7-deficient mice show impaired matu-
ration of reticulocytes, suggesting that autophagy is required for
loss of mitochondria as erythroid cells differentiate (Kundu et al.,
2008; Zhang et al., 2009). Increased numbers of mitochondria
and elevated ROS levels have been seen in focal adhesion
kinase family interacting protein of 200 kDa (FIP200)-deleted
fetal HSCs, resulting in defects in stem cell function. Similarly,
conditional Atg7-deficient mice show loss of normal HSC func-
tion and death within weeks after gene deletion. The HSC
compartment of these mice displays an accumulation of mito-chondria and ROS, as well as increased proliferation and DNA
damage. Atg7-deficient LSK cells also fail to reconstitute the
hematopoietic system of lethally irradiated mice (Mortensen
et al., 2011).
TCA cycle metabolites observed in some cancer cells have
also been seen in HSCs (Figure 5B). The genes encoding isoci-
trate dehydrogenase (IDH1 and IDH2) were identified asmutated
oncogenes in a high percentage of gliomas and acute myeloge-
nous leukemias (Parsons et al., 2008; Mardis et al., 2009). IDH1
and IDH2 are homodimeric, nicotinamide adenine dinucleotide
phosphate (NADP+)- and NAD+-dependent enzymes, respec-
tively. Both convert isocitrate to 2-OG and reside in the cyto-
plasm and mitochondria. IDH2 activity is a rate-limiting step in
the TCA cycle, which is dependent on ATP concentration, while
IDH1 functions in anaerobic states. Metabolic profiling showed
that cells expressing mutant IDH1 or IDH2 generated high levels
of 2-hydroxyglutarate (2-HG), a metabolite also detected in
leukemic cells (Ward et al., 2010; Gross et al., 2010). Transduc-
tion of hematopoietic cells with IDH2 mutant constructs impairs
their differentiation (Figueroa et al., 2010). The mutated IDH-
mediated neoreaction requires 2-OG derived from glutamine.
Glutamine is converted to glutamate by glutaminase and
then further catabolized to 2-OG to enter the TCA cycle. Glutami-
nolysis is controlled by c-Myc through a coordinated transcrip-
tional program (Wise and Thompson, 2010; Shanware et al.,
2011). Many cancer cells cannot survive in the absence of exog-
enous glutamine and exhibit ‘‘glutamine addiction’’ (Eagle,
1955).
In conjunction with 2-OG, the ten-eleven translocation 2
(TET2) loss induces increased HSC self-renewal and myeloid
transformation resulting in conditions such as AML and myelo-
dysplastic syndrome (MDS) (discussed in Cimmino et al., 2011).
TET2 encodes an O2-binding, 2-OG-dependent enzyme that
catalyzes the conversion of 5-methylcytosine to 5-hydroxyme-
thylcytosine, leading the subsequent DNA demethylation (Ko
et al., 2010). Expression ofmutant IDHmimics the loss of function
of TET2. Cytosine methylation is the major covalent modification
of genomic DNA and may play important roles in regulation of
the epigenetic states of HSCs (Cimmino et al., 2011).
Bioenergetic Signaling in HSCs
When stem cells proliferate, the phosphatidylinositol 3-kinase
(PI3K)/Akt/mTOR pathway is activated by growth factors and
nutrients such as glucose and amino acids (Yuan and Cantley,
2008) (Figure 6). Increased PI3K activity leads to increases in
cellular phosphatidylinositol 3,4-bisphosphate [PI(3,4)P2] and
phosphatidylinositol 3,4,5-triphosphate [PI(3,4,5)P3]. Binding
of 3-phosphoinositides induces a conformational change in
Akt, enabling corecruited 3-phosphoinositide-dependent pro-
tein kinase 1 to access the activation loop. Constitutively active
Akt signaling causes accelerated proliferation and depletion of
HSCs (Kharas et al., 2010). Although loss of Akt1 or Akt2 does
not lead to abnormal hematopoiesis (Mogi et al., 2003), HSCs
in Akt1/Akt2 double knockout mice remain in a constantly quies-
cent state and cannot differentiate into MPPs (Juntilla et al.,
2010). In contrast, deletion of Pten, a PIP3 phosphatase, induces
constitutively activated PI3K/Akt signaling, resulting in an accel-
erated cell cycle, and eventually leads to HSC exhaustion (Yil-
maz et al., 2006; Zhang et al., 2006). The reconstitution capacityCell Stem Cell 9, October 7, 2011 ª2011 Elsevier Inc. 303
Figure 6. HSC Signaling Pathways Governing Quiescence and
Cycling
The PI3K/Akt pathway is activated under conditions of high oxygen or high
nutrients, an activity accompanied by enhanced protein synthesis, oxidative
phosphorylation, and ROS generation. Overactivation of the Akt pathway
exhausts HSCs through a ROS-independent manner. Quiescent HSCs main-
tain low ROS levels via several systems, including promotion of glycolysis
and autophagy, and upregulation of FoxO proteins. Lkb1 may facilitate HSC
maintenance through distinct mechanisms.
Cell Stem Cell
Reviewof Pten/mice is, however, restored by p53 or p16Ink4a deletion
(Lee et al., 2010). Analysis of tissue-specific knockout of an
inhibitor of mTOR, tuberous sclerosis complex 1 (Tsc1), revealed
that the mTOR pathway was overactivated in the hematopoietic
system of mutant mice. HSCs were no longer quiescent and lost
reconstitution capacity (Chen et al., 2008; Gan et al., 2008). Intra-
cellular ROS levels were elevated and the number of mitochon-
dria increased in Tsc1-deleted HSCs. These data indicate that
mTOR is a critical modulator of stem cell maintenance and that
two tumor suppressors, Pten and Tsc1, serve as important nega-
tive regulators of PI3K/mTOR signaling in HSCs.
Recently, a different signaling pathway linking Akt/mTOR with
HSC metabolism has been delineated. The tumor suppressor
liver kinase B1 (Lkb1) is a serine/threonine kinase that positively
regulates AMPK, which in turn senses the AMP/ATP ratio (Hsu
and Sabatini, 2008). AMPK phosphorylation inhibits mTOR,
leading to reduced cell growth and proliferation. Thus, Lkb1/
AMPK signaling regulates cell metabolism in response to
changes in ATP availability. Mutations in the human LKB1 gene
result in a gastrointestinal polyposis disorder with increased
cancer predisposition (Peutz-Jeghers syndrome). Three groups
have independently identified an indispensable role for Lkb1 in
HSC maintenance (Gan et al., 2010; Gurumurthy et al., 2010;
Nakada et al., 2010). All three papers reported that conditional
Lkb1 knockout mice show gradually impaired hematopoiesis fol-
lowed by transient increases in the number of hematopoietic
progenitors and loss of reconstitution capacity after BM trans-
plantation. Importantly, the Lkb1 null phenotype is not rescued
by activation of AMPK, indicating that Lkb1 maintains HSC qui-
escence through different mechanisms, such as by modulating
mitochondrial function through PGC-1a.304 Cell Stem Cell 9, October 7, 2011 ª2011 Elsevier Inc.To gain insight into how Lkb1 mediates its developmental
effects, van der Velden et al. (2011) generated zebrafish mutants
in the single fish Lkb1 ortholog. Lkb1 mutant zebrafish survived
the embryonic period, but rapidly exhausted their energy
resources and died prematurely from starvation. The metabolic
rate in Lkb1 mutants was attenuated following treatment with
the TOR inhibitor rapamycin or by crossing Lkb1 mutant zebra-
fish with Vhl mutant fish, in which constitutive HIF-1 signaling
results in reduced oxidative metabolism. Gurumurthy et al.,
(2010) analyzed metabolic alterations in Lkb1-deficient hemato-
poietic cells using a combination of liquid/gas chromatography
and mass spectrometry platforms. This analysis showed that
the Lkb1 mutant had significant alterations in lipid metabolism
in the Lin populations. Diminished mitochondrial function and
elevated fatty acid levels are consistent with a model in which
Lkb1 serves as a rheostat that sets the appropriate balance of
anabolic and catabolic activities in hematopoietic cells.
ROS Generation and Signaling in HSCs
Bioenergetic metabolism is accompanied by the generation of
ROS in mitochondria (Balaban et al., 2005). ROS is a collective
term for various oxygen species that are more reactive than
dioxygen. Superoxide, hydrogen peroxide, hydroxyl radicals,
and singlet oxygen are all components of ROS. In addition,
superoxide can react with nitric oxide to form peroxinitrate.
Oxidative stress occurs when ROS production exceeds the
capacity of antioxidant systems to control ROS levels. High
doses of ROS can oxidize nucleic acids, lipids, proteins, or
carbohydrates, and excessive ROS promotes cellular senes-
cence, apoptosis, or carcinogenesis (Harman, 1956; Balaban
et al., 2005).
Under physiological conditions, mitochondria are the principal
source of ROS. Blood-borne oxygen enters mitochondria, binds
to COX, and serves as the terminal electron acceptor. However,
electrons may escape the electron transport chain prematurely
(at complex I or III) and react with O2 to form superoxide, which
is immediately converted to hydrogen peroxide bymitochondrial
manganese superoxide dismutase (MnSOD, SOD2) (Pervaiz
et al., 2009). Hydrogen peroxide is either converted to a highly
toxic hydroxyl radical by acquisition of another electron or elim-
inated by glutathione peroxidase (Gpx) (Cohen and Hochstein,
1963), peroxiredoxin (Prx) (Hofmann et al., 2002), or catalase
(Michiels et al., 1994). Aerobic organisms have not only devel-
oped defense mechanisms against ROS, they in fact also use
them as signal transducers in cell survival and proliferation activ-
ities (Chen and Pervaiz, 2007).
Mammalian HSCs, whose redox regulation is under intense
investigation, are more vulnerable to ROS than progenitors and
they lose stem cell capacity and die after ROS exposure. When
HSCs were stained with dihydrodichlorofluorescein diacetate,
which is converted to the molecule dichlorofluorescein (DCF) in
the presence of ROS, DCFhigh and DCFlow HSCs were seen
and the latter retained higher reconstitution ability than the
former (Jang and Sharkis, 2007). Interestingly, the DCFhigh frac-
tion had higher myeloid differentiation capacity than did DCFlow
cells, indicating that the DCFhigh fraction is ‘‘myeloid shifted,’’
a characteristic of senescent HSCs. Treatment of the DCFhigh
fraction with antioxidants or p38 MAPK inhibitors, which protect
HSCs against ROS damage, restored colony-forming capacity
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levels, it is important to monitor the level of oxygen and ROS
more accurately using in vivo cellular imaging (Lewandowski
et al., 2010) or, potentially, a recently-developed ROS detection
method in addition (Abo et al., 2011). A recent study in
Drosophila concluded that ROS prime hematopoietic progeni-
tors were a population similar to mammalian myeloid progenitor
cells in terms of differentiation, suggesting that ROS functions as
a differentiation factor in this context (Owusu-Ansah and Bane-
rjee, 2009). In cardiac and embryonic stem cells, physiological
levels of intracellular ROS are required to maintain genomic
stability through activation of DNA repair pathways (Li and Mar-
ba´n, 2010). Thus, the effect of ROS on HSC function likely
depends on the level and the exposure period. ROS-dependent
HSC proliferation plays an important role in the early steps of
hematopoietic reconstitution after HSC transplantation (Lewan-
dowski et al., 2010). Taken together, these findings indicate
that the effect of ROSmay depend on the stem cell cycling state,
although in general ROS induces cell cycling, resulting in stem
cell differentiation. Therefore, fine-tuning of ROS levels is essen-
tial for HSC maintenance.
Interaction of ROS Regulators in HSCs
ROS are required for normal cellular homeostasis, and their
levels are precisely regulated. The mechanism controlling HSC
redox status has been investigated using relevant gene-targeted
mice, which exhibit elevated ROS levels in HSCs associated
with defective HSC self-renewal, apoptosis, and differentia-
tion. Several regulatory molecules, including polycomb, DNA
damage-related, and anti-oxidant proteins, participate in ROS
regulation in HSCs (Figure 6).
Bmi1 and p16Ink4a
Polycomb proteins form a class of epigenetic modulators that
assemble in multimeric complexes and transcriptionally repress
target genes through histone modifications (Sauvageau and
Sauvageau, 2010). Bmi1 was the first polycomb protein shown
to have a role in HSC regulation, and it is the best characterized
thus far. Bmi1/ mouse HSCs exhibit premature senescence,
develop progressive BM hypoplasia, and die quickly (2 months)
after birth (Park et al., 2003; Lessard and Sauvageau, 2003).
Although Bmi1/ mice have an apparently normal pool of fetal
liver HSCs, transplantation of Bmi1/ fetal liver HSCs into
lethally irradiated recipients results in only transient reconstitu-
tion of hematopoiesis. Deficient self-renewal was also observed
in normal NSCs and leukemia stem cells lacking Bmi1, indicating
that Bmi1 is a general regulator of stem cell self-renewal (Park
et al., 2003; Lessard and Sauvageau, 2003; Molofsky et al.,
2003).
The downstream targets of Bmi1 include gene products of the
p16Ink4a/p19Arf locus, and HSCs from Bmi1/ mice express
increased p16Ink4a and p19Arf levels. Enforced expression of
p16Ink4a and p19Arf in HSCs induces cell cycle arrest and
apoptosis, respectively. Conversely, deletion of both p16Ink4a
and p19Arf largely restores the ability of Bmi1/ stem cells to
self-renew (Oguro et al., 2006). Bmi1 also regulates mitochon-
drial ROS production (Liu et al., 2009). HSCs from Bmi1/
mice produce increased levels of ROS, which could also
contribute to induction of p16Ink4a expression and HSC senes-
cence. These findings demonstrate that Bmi1 promotes HSCself-renewal at least in part by inhibiting ROS production and
p16Ink4a expression to prevent cells from undergoing premature
senescence. Oxidative stress is implicated in activation of both
p38 MAPK and p53-p21CIP1/WAF1 signaling and, consequently,
in cell-cycle arrest and senescence (Muller, 2009).
p38 MAPK also plays a critical role in induction of senescence
via p16Ink4a upregulation. For example, a high level of Ras or Raf
activation induces senescence by ROS-mediated sustained
activation of p38 MAPK, which in turn upregulates p16Ink4a ex-
pression (Serrano et al., 1997). Treatment of HSCs with a p38
MAPK inhibitor antagonizes stem cell exhaustion during serial
transplantation (Ito et al., 2006). It would be interesting to know
whether treatment with a p38 MAPK inhibitor reverses senes-
cence in HSCs.
p16Ink4a and p19Arf are encoded by the Ink4a/Arf locus.
p16Ink4a causes Rb hypophosphorylation by inhibiting CDK4/6
activity, and suppresses E2F-dependent gene expression. Inac-
tivation of p53 prior to upregulation of p16Ink4a can prevent
senescence induction. However, once p16Ink4a is highly ex-
pressed, cell cycle arrest becomes irreversible by p53 downre-
gulation, indicating that activation of the p53 pathway plays an
important role in the initiation of senescence (Campisi, 2005;
Beause´jour et al., 2003). On the other hand, p19Arf competes
with p53 for binding to Mdm2, thereby inhibiting the ubiq-
uitination of p53 by Mdm2 (Sherr and Weber, 2000). Activation
of p53 by p19Arf can induce cellular senescence or apoptosis,
depending on which genes downstream of p53 are induced
following its activation. p53 protects stem cells from ROS
damage by regulating redox factors such as thioredoxin, metal-
lothioneins, and the redox-repair enzyme apurinic/apyrimidinic
endonuclease/redox effector factor-1 (APE/Ref-1) (Hafsi and
Hainaut, 2011). However, excessive p53 activation reportedly
depletes stem cells via ROS accumulation (Abbas et al., 2010).
ATM and ATR
ROS plays an essential role in the DDR and DNA repair. Preser-
vation of genome integrity via these responses is critical for
preventing disease, particularly cancer. The serine/threonine
kinases ataxia telangiectasia mutated (ATM), ATM- and Rad3-
related (ATR), and DNA-dependent protein kinase (DNA-PK)
are important for repair pathways. These proteins belong to
the phosphoinositide-3-like kinase kinase family and share
similar domain architecture and regulation (Shiloh, 2003). DSBs
activate ATMandDNA-PK, whereasmany types of DNAdamage
activate ATR, including DSBs, base adducts, and crosslinks
(Nam and Cortez, 2011).
ATM plays a major role in processing DNA damage and
in maintenance of genome integrity downstream of the p53-
dependent response to DSBs. In addition, ATM is physically
associated with telomeres and functions in telomere mainte-
nance (Herbig et al., 2004). Premature senescence in stem and
progenitor cells is evident in various organs ofAtm/mice (Nitta
et al., 2011; Takubo et al., 2008).Atm/mice also show a defect
in HSC self-renewal and exhibit a progressive decline in HSCs
with age (Ito et al., 2004). This defect can be rescued by
p16Ink4a downregulation through Bmi1 overexpression or by
suppression of p16Ink4a/Rb pathways through human papilloma-
virus protein E7 expression. However, overexpression of TERT
in Atm-deficient HSCs does not rescue cellular phenotypesCell Stem Cell 9, October 7, 2011 ª2011 Elsevier Inc. 305
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capacity of HSCs is normalized when the antioxidant N-acetyl
L-cysteine is administered to Atm/ mice, indicating a causa-
tive role for ROS in impaired function of Atm-deficient HSCs.
Moreover, ATM is reportedly a critical sensor of oxidative
stress (Guo et al., 2010). These findings indicate that ATM reg-
ulates HSC self-renewal by inhibiting ROS production and
p16Ink4a expression to prevent HSCs from undergoing premature
senescence.
The most critical signal for ATR activation probably involves
replication stress. ATR, unlike ATM and DNA-PK, is essential in
replicating cells. This requirement is probably a result of ATR
activation occurring in response to replication stress in every S
phase and perhaps due to its being involved in the regulation
of specific aspects of DNA replication, such as origin firing or
nucleotide production. Inducible ATR knockout mice show dra-
matic reductions in tissue-specific stem and progenitor cells
and exhaustion of tissue renewal and homeostatic capacity
(Ruzankina et al., 2007). Although it has not been shown that
ATR functions in HSCs, ATR is linked with a key molecule for
HSCs and leukemic cells, that resulting from the MLL gene,
which causes a deregulation of the S phase check point.
FoxO and AKT
Accumulating evidence suggests that forkhead homeobox type
O (FoxO) transcription factors play a conserved role in cellular
adaptation to stress stimuli and in regulating HSC redox status
(Storz, 2011). In mammals the FoxO family is composed of
FoxO1, FoxO3, FoxO4, and FoxO6. Foxo3a knockout mice
show abnormally high ROS levels due to reduced expression
of antioxidant enzymes such as catalase and SOD2, which are
downstream targets of FoxO3a (Miyamoto et al., 2007). Similar
to the Atm/ phenotype, excessive ROS induces phosphoryla-
tion of p38MAPK, resulting in p16Ink4a and p19Arf expression and
loss of HSC self-renewal capacity. Tothova et al. (2007) analyzed
HSCs of Foxo1//Foxo3a//Foxo4/ triple knockout mice
and found decreased numbers of HSCs with accelerated cell
cycling and apoptosis, defects rescued by administration of anti-
oxidants. These results support the idea that FoxOs mediate
ROS regulation in HSCs and maintain their self-renewal ability.
FoxO3a also reportedly directly interacts with ATM, inhibiting
ROS generation and potentiating the DDR (Tsai et al., 2008).
In response to hypoxia, FoxO3a mRNA levels accumulate in
an HIF-1-dependent manner, resulting in enhanced FoxO3a
activity. Bakker et al. (2007) showed that FOXO3a inhibits HIF-
1-induced apoptosis by stimulating the transcription of Cited2.
Cited2 is an essential regulator of adult HSCs, as shown using
conditional knockout mice (Kranc et al., 2009). Several upstream
signal transduction pathways regulate FoxO function both
negatively and positively through phosphorylation. The best-
characterized negative regulator is the PI3K/Akt pathway (Brunet
et al., 1999) (also see above in this article). Activated Akt phos-
phorylates FoxO proteins at three consensus Akt phosphoryla-
tion sites (Storz, 2011). FoxOs are then exported from the
nucleus to the cytoplasm by 14-3-3 proteins, resulting in loss
of target gene transcription (Brunet et al., 2002). In the hemato-
poietic system, the intracellular localization of FoxO3a varies
according to differentiation stage. In HSCs, FoxO3a is nuclear,
whereas it localizes in the cytoplasm in progenitors. Thus, the306 Cell Stem Cell 9, October 7, 2011 ª2011 Elsevier Inc.PI3K/Akt pathway is suppressed in HSCs and activated in
hematopoietic progenitors (Miyamoto et al., 2007; Yamazaki
et al., 2006).
FoxO is positively regulated by AMPK (Greer et al., 2007) and
induced by Jun N-terminal kinase (JNK)-mediated phosphoryla-
tion in response to hydrogen peroxide (Essers et al., 2004). JNK
phosphorylates two FoxO threonine residues, leading to nuclear
translocation (Kops et al., 2002). Additionally, posttranslational
modifications such as acetylation by CBP/p300 induce FoxO-
mediated cellular detoxification, cell cycle arrest, and DNA repair
or apoptosis in response to ROS (van der Horst and Burgering,
2007). Although acetylation of FoxO family members by CBP/
p300 has yet to be reported in HSCs, posttranslational activation
by CBP/p300 should be investigated, given the crucial role of
CBP/p300 in both HSC maintenance and differentiation (Rebel
et al., 2002). In addition to HSCs, FoxO3 expression is enhanced
in erythropoiesis. Expression of ROS scavenging enzymes is de-
creased in FoxO3a-deficient erythroid cells (Marinkovic et al.,
2007).
Heme Oxygenase
Heme oxygenase-1 (HO-1) is a major stress-responsive antioxi-
dant enzyme that plays a central role in cellular defenses against
oxidative and nitrosative stresses (Was et al., 2010). HO-1, the
rate-limiting enzyme in heme catabolism, catalyzes stereospe-
cific degradation of heme to biliverdin, with concurrent release
of ferrous iron and carbon monoxide. HSCs from irradiated,
heterozygous, HO-1-deficient (Ho1+/) mice show reduced
capacity for hematopoietic reconstitution, suggesting that HO-1
plays a key role in HSC maintenance (Cao et al., 2008). HO-1 is
regulated by NF-E2-related factor-2 (Nrf2) and Keap1. Nrf2,
a bZIP transcription factor, acts as a master regulator of cellular
defenses against oxidative stress. Hochmuth et al. (2011) report
that Nrf2 is constitutively active inDrosophila intestinal stem cells
and that Nrf2 repression by its negative regulator Keap1 is
required for proliferation. In resting cells, Nrf2 is retained in the
cytoplasm with Keap1, but exposure to ROS releases Nrf2
from Keap1 and allows Nrf2 to move to the nucleus (Itoh et al.,
1999). These results highlight a critical redox management sys-
tem regulating stem cell function in high-turnover tissues. Very
recently, it was reported that oncogenes such as Kras, Braf,
and Myc induce Nrf2 transcription, promoting ROS detoxifica-
tion and contributing to tumorigenesis (DeNicola et al., 2011).
These activities may be relevant to cancer stem cells (CSCs),
which show low levels of ROS (Diehn et al., 2009). The low levels
of ROS may be protumorigenic, since high levels of ROS induce
cell apoptosis. However, there is no information as yet about the
role of Nrf2 and Keap1 in HSCs.
Concluding Remarks
In this review, we have summarized studies regarding energy,
oxygen, and redox homeostasis in stem cells with an emphasis
on HSCs. These metabolic studies provide new insight into
stem cell biology. Stem cells are quiescent and exhibit few mito-
chondria, whereas progenitor cells are engaged in active cycling
and contain many mitochondria. Thus, stem cells and progeni-
tors have distinct metabolic states, and the transition from stem
to progenitor cell corresponds to a critical metabolic change,
namely one from glycolysis to oxidative phosphorylation.
Cell Stem Cell
ReviewDormancy or long-term quiescence is likely a fundamental attri-
bute of adult tissue stem cells, with some exceptions such as
intestinal stem cells. Dormancy may be a crucial mechanism for
the stress resistance of both normal cells and CSCs. Many inter-
esting questions remain; for example, how do stem cells convert
fromquiescence to cycling or vice versa? In this process,which is
the first event: metabolic alteration, oxygen concentration, cyto-
kine stimulation, or cell contact regulation?What is the difference
between anaerobic glycolysis and aerobic glycolysis in HSCs,
and which is seen in cancer cells? Are there any other distinctive
metabolic characteristics in HSCs? An improved understanding
of stem cell metabolism will also improve efforts to maintain,
expand, and manipulate HSCs ex vivo to realize their potential
therapeutic benefits in regenerative medicine. Important clues
have already come from elucidation of stem cell bioenergetics
and have major implications for therapies aimed at either gener-
ating or eliminating stem cells.REFERENCES
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